Philogen to hold a Webinar on Wednesday 29th of September 2021 at 12:00 ET / 17:00 BST / 18:00 CEST (Please find the link to this Webinar here) Download pdf file
Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read More
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
Philogen annuncia i risultati del primo trimestre 2021 e fornisce un aggiornamento sui progressi della pipeline
The Board of Directors approves the net financial position for the first quarter of 2021 in the amount of 104,668 thousand euro, and acknowledges the progress of the main clinical trials on Nidlegy™ and Fibromun in line with the expected timelines (Price...